NeoProteomics is a respected provider of research services and tools to help clients unravel the complexities of pharmaceutical and biological research. Headquartered in Cleveland, Ohio, the company was founded in 2006 by Dr. Mark Chance, director of the Center for Proteomics and Bioinformatics at Case Western Reserve University (CWRU), John L. H. Schenkel, Jr., and Steven Chance. Our purpose is to evaluate and commercialize technologies developed at CWRU. NeoProteomics has licensed an attractive IP portfolio from CWRU, which serves as the foundation of our cutting-edge services designed to help researchers increase the speed and accuracy of their biologics and small molecular drug development. NeoProteomics currently provides expert services and tools to numerous partner companies and research laboratories worldwide.
President, CEO, & Co-Founder
Over 25 years of business development, marketing, and management experience.
Directs the day-to-day business activities, including business development, strategic direction, and operations
Chief Scientific Officer & Co-Founder
Director of the Center for Proteomics and Bioinformatics and vice dean for research at Case Western Reserve University.
Provides scientific direction, product, and project management.
Secretary & General Counsel
Former executive vice president and general counsel of Teleflex Corporation.
Handles all legal, IP, patents, and contractual engagements.
Recognized expert in structural biology and CL-MS with over 20 years of experience with numerous collaborations and publications.
Serves as project manager and primary point of contact for all client engagements.